8th Feb 2023 14:35
Craven House Capital PLC - London-based investment fund with minority shareholding in four Swedish-managed eCommerce and pharmaceutical businesses - Says Bio Vitos, a company that sells omega 3 tablets and in which Craven House owns a 24.5% stake, enters into an agreement to buy an 88% stake in Hemcheck Sweden AB, a company focused on detecting hemolyzed blood samples. Hemolyzed means red blood cells in a sample burst, usually rendering it unable to yield a test result. Bio Vitos will pay Hemcheck SEK5.2 million, around GBP407,249, in cash for business and assets.
Current stock price: USD0.35
12-month change: up 59%
By Tom Budszus, Alliance News reporter
Comments and questions to [email protected]
Copyright 2023 Alliance News Ltd. All Rights Reserved.
Related Shares:
Craven House Capital